<DOC>
	<DOC>NCT00432302</DOC>
	<brief_summary>The purpose of this study is to: a) Determine how the body takes up the test drug and distributes it into various body organs and tissues, how it processes the drug and how it ultimately removes it; and b) Examine how well the test drug works against cancer, and whether it is safe and tolerable to take</brief_summary>
	<brief_title>Investigation of Mass Balance of the Test Drug and Major Metabolites</brief_title>
	<detailed_description>The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer Schering Pharma AG, Germany.</detailed_description>
	<mesh_term>Epothilones</mesh_term>
	<criteria>Male ≥ 18 years; female ≥ 50 years without childbearing potential (confirmed by either: age ≥ 60; or history of hysterectomy; or hormone analysis in serum: Estradiol ≤ 20 pg/mL and follicle stimulating hormone ≥ 40 IU/L) Solid tumor Adequate function of major organs Failed previous cancer treatment Peripheral venous access Concurrent severe and/or uncontrolled disease Brain tumors Marked constipation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Tumor</keyword>
	<keyword>Malignancy</keyword>
	<keyword>Mass Balance</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Drug</keyword>
	<keyword>Cancer Treatment</keyword>
	<keyword>Intravenous Infusion</keyword>
	<keyword>Epothilone</keyword>
	<keyword>Solid Tumor</keyword>
</DOC>